Italy: A founding partner and longstanding leader in vaccine financing
Italy: A founding partner and longstanding leader in vaccine financing
25 March 2026
Italy commitment
For nearly two decades, Italy has been a leading supporter of global immunisation through IFFIm, of which it is a founding member.
Announcements
Since 2006, Italy has committed €654 million (US$ 821 million) to IFFIm, making it the Facility’s fourthlargest donor. This long-standing investment has played a pivotal role in enabling Gavi to expand equitable access to life-saving vaccines worldwide. Italy’s engagement has also included other innovative financing mechanisms, such as the Advance Market Commitments (AMCs), further reinforcing its strategic commitment to sustainable and impactful global health financing.
From the beginning, Italy recognised IFFIm’s value as a unique and flexible financing tool. By enabling frontloaded funding, IFFIm allows Gavi to substantially finance immunisation programmes as well as responding rapidly to health emergencies and to invest early in programmes that yield long-term impact. Italy’s regular and predictable contributions have been particularly vital in strengthening Gavi’s ability to scale up immunisation during crises such as the COVID-19 pandemic, where IFFIm resources helped accelerate global access through the COVID-19 Vaccines Global Access (COVAX). Beyond emergency response, IFFIm also plays a key role in advancing Gavi’s broader mission of market shaping, helping to reduce vaccine prices and ensure that immunisation remains affordable and accessible.
Leone Gianturco, Head of Global Public Goods at the Italian Treasury and Alternate Board Member on the Gavi Board, reflected on Italy’s role:
“Italy’s renewed contribution to IFFIm for Gavi’s 2026–2030 strategic period reaffirms its commitment to innovative financing for global health. Building on a long-standing partnership with Gavi, this support goes beyond a financial pledge: it reflects Italy’s strategic and sustained use of innovative tools to help ensure equitable access to life-saving vaccines for the world’s most vulnerable populations.”
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.